In 2020, we added two significant patents to our portfolio that protect market entry and lead to the creation of immune-compatible, patient-specific donors utilizing CRISPR technology. Our third patent, currently under review, applies artificial intelligence to the genetic design of your unique donor.

​

U.S. Patent No. 10,799,614

Awarded October 13, 2020

​

Xenotransplantation Products and Methods, describes how to make genetically engineered porcine donor acceptable for human use, regardless of the specific genetic alterations applied. It details the essential “rate-limiting” processes and conditions necessary to make any source animal “clinically acceptable” to the FDA. This patent represents a substantial barrier to entry for others in the xenotransplantation market.
 

U.S. Patent App. No. 16/830,213

Allowed for Award November 10, 2020

​

Personalized Cells, Tissues, and Organs for Transplantation from a Humanized, Bespoke, Designated-Pathogen Free, Non-Human Donor, covers the concepts underpinning the precise genetic modifications and processes we have designed to create “humanized” and “personalized” porcine donor source animal for transplantation of immune-compatible cells, tissues, and organs.

 

U.S. Provisional Patent App. No. 63/034,140

Filed June 3, 2020

​

Computational and Predictive Design of Humanized, Bespoke, Non-Human Donor for Transplantation of Personalized Cells, Tissues, and Organs, describes how to harness a predictive algorithm using high-throughput computational mathematics (employing widely available and accessible “base-pair” level data sets) and in silico modeling of gene and protein variation in order to improve on the current standard of human-to-human transplantation today and give this non-human source an even greater advantage. This non-provisional patent application was submitted June 2020 and is anticipated for public visibility by  December 2020.